Table 2.

Dosing of HF drugs at time of implantation and last follow‐up

	Implant	Last follow‐up	P‐value
Beta‐blocker
Yes	43 (89.6%)	40 (83.3%)	0.375
% of target dose	54 ± 30	55 ± 34	0.530
ACEi/ARB/ARNI
Yes	41 (85.4%)	33 (68.8%)	0.021
% of target dose	42 ± 14	38 ± 24	0.184
MRA
Yes	39 (81.3%)	38 (79.2%)	1.000
Spironolactone equivalent (mg)	24 ± 8	24 ± 12	0.812
Loop diuretic
Yes	47 (97.9%)	47 (97.9%)	1.000
Furosemide equivalent dose (mg)	97 ± 89	154 ± 195	0.005
Thiazide diuretic
Yes	9 (18.8%)	10 (20.8%)	1.000
HCT equivalent dose (mg)	29 ± 13	30 ± 11	1.000
SGLT2 inhibitor	1 (2.1%)	8 (16.7%)	0.016
Ivabradine	2 (4.2%)	2 (4.2%)	1.000
Digoxin	8 (16.7%)	8 (16.7%)	1.000

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitor; HCT, hydrochlorothiazide; MRA, mineralocorticoid receptor antagonist; SGLT2, sodium glucose cotransporter 2.

% of target dose ranges from 0 to 100 and indicates how much of the recommended target dose in heart failure is achieved. For furosemide equivalent dose: 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide. For HCT equivalent dose: 25 mg hydrochlorothiazide = 25 mg chlortalidone = 2.5 mg metolazone = 1.25 mg indapamide.

P‐value in bold indicates P < 0.05.